INGN 225

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameINGN 225
Drug Alias NameAdenovirus-p53 transduced dendritic cell vaccine (H. Lee Moffitt Cancer Center and Research Institute)Ad.p53 DC vaccine (H. Lee Moffitt Cancer Center and Research Institute)P53 immunotherapy (H. Lee Moffitt Cancer Center and Research Institute)Autologous dendritic cell adenovirus p53 vaccine (H. Lee Moffitt Cancer Center and Research Institute)Dendritic cell based p53 vaccine +[6] 
ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine
Mechanisms of ActionImmunostimulantsTumor protein p53 stimulantsP53 gene stimulants
TargetsTumor protein p53
Therapy Area/IndicationsSolid tumoursSmall Cell Lung CarcinomaLung Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesH Lee Moffitt Cancer Center & Research Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesH Lee Moffitt Cancer Center & Research InstituteUniversity of Nebraska
Active IndicationsN/A
Inactive IndicationsSolid tumoursSmall Cell Lung CarcinomaLung Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksN/A